Evidence map›Paper›PMID 42682505›Full record

ArticleFrontiers in oncology2026

Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HR

Yan Li, Bingyu Li, Xiaoping Ma, Dan Liu, Li Li, Zhenhui Zhao, Xiner Zhang, Bing Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan LiDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Bingyu LiDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Xiaoping MaDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Dan LiuDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Li LiDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Zhenhui ZhaoDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Xiner ZhangDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Bing ZhaoDepartment of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dalpiciclib shows satisfactory efficacy and safety in patients with hormone receptor-positive (HR Methods: This single-center retrospective study analyzed the data of 70 elderly patients (≥65 years) with HR Results: The objective response rate (ORR) was 14.3%, and the disease control rate was 94.3%. The ORR was higher in patients with first-line dalpiciclib-based therapy than in those with second-line therapy or above (24.4% vs. 0.0%) ( Conclusion: Dalpiciclib plus endocrine therapy possesses acceptable efficacy and safety for the treatment of elderly patients with HR

Indexed as

dalpiciclibefficacyelderlyHR+/HER2- advanced breast cancersafety

Identifiers

PMID42682505
PMCPMC13529596

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.